Cardiovascular Disease (CVD) in Haemophilia
|ClinicalTrials.gov Identifier: NCT01303900|
Recruitment Status : Unknown
Verified February 2011 by UMC Utrecht.
Recruitment status was: Enrolling by invitation
First Posted : February 25, 2011
Last Update Posted : February 25, 2011
Life expectancy of hemophilia patients has improved considerably during the past decades and is approaching that of the general population. Hemophilia patients are therefore likely to be confronted with age-related disorders in addition to their primary illness and related diseases. Little is known about the occurrence of age-related co-morbidity, especially cardiovascular disease (CVD), in these patients. Low clotting factor levels are hypothesized to protect against both atherosclerosis and thrombus formation, resulting in a reduced risk of ischemic CVD. CVD mortality has been reported to be lower in haemophilia patients than in the general population, but data on non-fatal CVD are lacking, and no adjustment for CVD risk factors has been made so far.
The aim of our study is to assess the occurrence of CVD and its risk factors in a large cohort of haemophilia patients.
In this prospective multicenter cohort study in a group of 700-800 male patients with haemophilia A or B aged 30 years or older from The Netherlands and the UK, data on CVD history and CVD risk factors will be collected at baseline and compared with the general age-matched male population. Overall QRISK2 cardiovascular risk scores will be calculated and also compared with the general population. During a follow-up period of 5 and 10 years the occurrence of CVD events will be recorded and compared with the expected occurrence based on the QRISK2 scores and with data from the general population.
|Condition or disease|
|Haemophilia Cardiovascular Disease|
|Study Type :||Observational|
|Estimated Enrollment :||750 participants|
|Official Title:||Cardiovascular Disease in Adult Haemophilia Patients|
|Study Start Date :||January 2009|
- Ischemic cardiovascular disease [ Time Frame: After 5 and 10 years ]
- Cardiovascular disease risk factors [ Time Frame: At baseline ]
- Association between clotting factor concentrate administration and cardiovascular events [ Time Frame: 5-10 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01303900
|Division of Haemostasis and Thrombosis, Department of Haematology, University Medical Center Groningen|
|Van Creveldkliniek, University Medical Center Utrecht|
|School of Medicine, Cardiff University and University Hospital of Wales|
|Cardiff, United Kingdom|
|Glasgow Haemophilia and Thrombosis Centre, Royal Infirmary|
|Glasgow, United Kingdom|
|Katharine Dormandy Haemophilia Centre and Haemostasis Unit, Royal Free Hospital|
|London, United Kingdom|
|Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital|
|Sheffield, United Kingdom|